Mp. Cooreman et al., Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen, J BIOMED SC, 8(3), 2001, pp. 237-247
Hepatitis B virus surface antigen (HBsAg) vaccination has been shown to be
effective in preventing hepatitis B virus (HBV) infection. The protection i
s based on the induction of anti-HBs antibodies against a major cluster of
antigenic epitopes of HBsAg, defined as the 'a' determinant region of small
HBsAg. Prophylaxis of recurrent HBV infection in patients who have undergo
ne liver transplantation for hepatitis B-related end-stage liver disease is
achieved by the administration of hepatitis B immune globulins (HBIg) deri
ved from HBsAg-vaccinated subjects. The anti-HBs-mediated immune pressure o
n HBV, however, seems to go along with the emergence and/or selection of im
mune escape HBV mutants that enable viral persistence in spite of adequate
antibody titers. These HBsAg escape mutants harbor single or double point m
utations that may significantly alter the immunological characteristics of
HBsAg. Most escape mutations that influence HBsAg recognition by anti-HBs a
ntibodies are located in the second 'a' determinant loop. Notably, HBsAg wi
th an arginine replacement for glycine at amino acid 145 is considered the
quintessential immune escape mutant because it has been isolated consistent
ly in clinical samples of HBIg-treated individuals and vaccinated infants o
f chronically infected mothers. Direct binding studies with monoclonal anti
bodies demonstrated a more dramatic impact of this mutation on anti-HBs ant
ibody recognition, compared with other point mutations in this antigenic do
main. The clinical and epidemiological significance of these emerging HBsAg
mutants will be a matter of research for years to come, especially as data
available so far document that these mutants are viable and infectious str
ains. Strategies for vaccination programs and posttransplantation prophylax
is of recurrent hepatitis need to be developed that may prevent immune esca
pe mutant HBV from spreading and to prevent these strains from becoming dom
inant during the next decennia.